AbelZeta Pharma is a clinical-stage biopharmaceutical company developing CAR-T cell therapies and antibody-based immuno-oncology treatments, with operations in the US and China.
PR Newswire reports AbelZeta Pharma regained global rights to C-CAR039 (Prizlon-cel) and received FDA clearance of an IND application in large B-cell lymphoma.